Cortechs.ai, a pioneering leader in advanced imaging solutions for healthcare professionals, is thrilled to announce its recent funding achievement of $14 million. This significant capital infusion will play a crucial role in further enhancing the capabilities of Cortach.ai's flagship product, NeuroQuant®, and expanding its reach into clinics and research centers globally. NeuroQuant® is a groundbreaking medical device that has been FDA cleared and CE marked, uniquely capable of automatically detecting and quantifying brain atrophy through MRI images – a transformative innovation for radiologists, neurologists, and oncologists alike. With a mission to revolutionize patient care, the Cortechs.ai team, consisting of talented scientists, engineers, and clinical specialists, is committed to improving the diagnosis and treatment of neurodegenerative diseases and cancers. The newly acquired funds will be directed toward advancing the technological robustness of NeuroQuant® and expanding its capabilities, as well as enhancing marketing strategies to penetrate new markets and increase user accessibility. By harnessing this funding, Cortechs.ai aims to further democratize access to critical diagnostic information, allowing healthcare providers to adopt cutting-edge tools that lead to faster and more accurate patient diagnoses. As the demand for precise and efficient diagnostic solutions grows, Cortechs.ai is positioned to stand at the forefront of medical innovation, embodying a brighter future for patients battling complex neurological conditions.








